Neurological symptoms and axonal damage in COVID-19 survivors: are there sequelae?
Authors:
Open Access
- 7 August 2021
- journal article
- research article
- Published by Springer Nature in Immunologic Research
- Vol. 69 (6) , 553-557
Abstract
The persistence of neurological symptoms after SARS-CoV-2 infection, as well as the presence of late axonal damage, is still unknown. We performed extensive systemic and neurological follow-up evaluations in 107 out of 193 consecutive patients admitted to the COVID-19 medical unit, University Hospital of Verona, Italy between March and June 2020. We analysed serum neurofilament light chain (NfL) levels in all cases including a subgroup (n = 29) of patients with available onset samples. Comparisons between clinical and biomarker data were then performed. Neurological symptoms were still present in a significant number (n = 49) of patients over the follow-up. The most common reported symptoms were hyposmia (n = 11), fatigue (n = 28), myalgia (n = 14), and impaired memory (n = 11) and were more common in cases with severe acute COVID-19. Follow-up serum NfL values (15.2 pg/mL, range 2.4–62.4) were within normal range in all except 5 patients and did not differentiate patients with vs without persistent neurological symptoms. In patients with available onset and follow-up samples, a significant (p < 0.001) decrease of NfL levels was observed and was more evident in patients with a severe acute disease. Despite the common persistence of neurological symptoms, COVID-19 survivors do not show active axonal damage, which seems a peculiar feature of acute SARS-CoV-2 infection.Keywords
Funding Information
- Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona
- Brain Research Foundation Verona, Italy (2020)
- Università degli Studi di Verona
This publication has 13 references indexed in Scilit:
- Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19Neurology, 2020
- Neurological associations of COVID-19The Lancet Neurology, 2020
- Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19Journal of Neurology, 2020
- Nervous system: subclinical target of SARS-CoV-2 infectionJournal of Neurology, Neurosurgery & Psychiatry, 2020
- Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adultsScandinavian Journal of Clinical and Laboratory Investigation, 2020
- Serum and CSF neurofilament light chain levels in antibody-mediated encephalitisJournal of Neurology, 2019
- Neurofilament changes in serum and cerebrospinal fluid after acute ischemic strokeNeuroscience Letters, 2019
- Serum neurofilament lightNeurology, 2018
- Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatmentAIDS, 2018
- Neurofilaments as biomarkers in neurological disordersNature Reviews Neurology, 2018